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Background: Susceptibility to bleomycin-induced chromatid
breaks in cultured peripheral blood lymphocytes may reflect
the way a person deals with carcinogenic challenges. This
susceptibility (also referred to as mutagen sensitivity) has
been found to be increased in patients with environmentally
related cancers, including cancers of the head and neck,
lung, and colon, and, in combination with carcinogenic ex-
posure, this susceptibility can greatly influence cancer risk.
The purpose of this study was to assess the heritability of
mutagen sensitivity. Methods: Heritability was determined
by use of a maximum likelihood method that employed the
FISHER package of pedigree analysis. Bleomycin-induced
breaks per cell values for 135 healthy volunteers without
cancer were determined. These individuals were from 53
different pedigrees and included 25 monozygotic twin pairs
(n = 50), 14 pairs of dizygotes (twin pairs and siblings, n =
28), and 14 families selected on the basis of a first-degree
relative who was successfully treated for head and neck can-
cer and who had no sign of recurrence for at least 1 year. All
data were analyzed simultaneously, and different models of
familial resemblance were fitted to the data. All P values are
two-sided. Results: Our results showed no evidence for the
influence of a shared family environment on bleomycin-
induced chromatid breaks. Genetic influences, however,
were statistically significant (P = .036) and accounted for
75% of the total variance. Conclusions: The high heritability
estimate of the susceptibility to bleomycin-induced chroma-
tid breaks indicates a clear genetic basis. The findings of this
study support the notion that a common genetic susceptibil-
ity to DNA damage—and thereby a susceptibility to can-
cer—may exist in the general population. [J Natl Cancer Inst
1999;91:1125–30]
For cancers of the respiratory and upper digestive tracts, tra-
ditional epidemiology has identified smoking and alcohol intake
as major risk factors (1,2). These risk factors, however, cannot
adequately explain all cancer cases. Much emphasis has been
given on the value of molecular epidemiology for the refinement
of the estimation of environmentally related cancer risks (3,4).
Molecular epidemiology is a relatively new approach that incor-
porates individual biomarkers for cancer risk assessments in
populations. An interaction between exposure to carcinogens
and susceptibility factors was found to determine cancer risk.
Susceptibility biomarkers have been reported, for instance, on
carcinogen detoxification, carcinogen activation, and formation
of DNA adducts (5–7).
A functional approach to determine individual susceptibility
to carcinogenic assaults is to screen for chromatid breaks after in
vitro G2-phase bleomycin treatment of cultured peripheral blood
lymphocytes. For environmentally related cancers, such as colon
cancer, lung cancer, and head and neck squamous cell carcinoma
(HNSCC), the biologic relevance of this marker has been well
established (8,9). We and others (8–10) showed an increase in
the mean level of chromatid breaks per cell in cancer patients
compared with healthy control persons. This high level was
especially found in those patients with multiple primary tumors
(10). The mean number of breaks per cell score was not influ-
enced by smoking or alcohol use by the subjects. It was shown
in a meta-analysis that a high susceptibility (defined as 1.0 or
more breaks per cell) itself slightly increased cancer risk but did
not reach statistical significance. Of interest, however, in com-
bination with exposure to carcinogens, a large increase (up to an
odds ratio of 57.5) of risk for HNSCC was found (11).
For persons at high risk of cancer (particularly, members of
families with a high frequency of common cancers and HNSCC
patients who have been successfully treated for their primary
tumor and are at risk for a second tumor), it is important to
ascertain whether this susceptibility phenotype has a genetic
basis. Such knowledge will increase the value of this suscepti-
bility marker and encourage further studies of the (genetic)
mechanisms underlying this susceptibility. We investigated the
heritability of the susceptibility to chromatid breaks in pedigrees
from HNSCC patients who have been successfully treated and
have no evidence of cancer recurrence for at least 1 year. Be-
cause familial resemblance can be due to shared environment as
well as to shared genes, the number of chromatid breaks was
also assessed in 25 pairs of monozygotic twins (unrelated to the
HNSCC patients), who are genetically identical. Any larger re-
semblance for monozygotic twins compared with the first-
degree relatives (who share, on average, 50% of their genes)
could suggest the importance of genetic factors. In this study, we
employed the powerful tool of pedigree analysis to estimate the
heritability of mutagen sensitivity.
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METHODS
Subjects
All subjects (n 4 135) whose data were used for the estimation of the
heritability of the susceptibility marker were healthy volunteers from 53 different
pedigrees and consisted of dizygotes (n 4 85; stratified in three groups on the
basis of their relation to the 14 HNSCC patients who were enrolled in this study;
I 4 siblings of the HNSCC patients [n 4 32]; II 4 offsprings of the HNSCC
patients [n 4 25]; III 4 dizygotes, volunteers unrelated to HNSCC patients [n
4 28]), and monozygotes, volunteers unrelated to HNSCC patients (group IV:
25 pairs of identical twins, n 4 50). Heparinized blood samples were collected
from the first-degree relatives (groups I and II) of 14 HNSCC patients previously
treated at our department and had no more evidence of any residual or recurrence
disease for at least 1 year (n 4 57). Heparinized blood samples were also
obtained from volunteers not related to HNSCC patients (group III, consisting of
14 dizygotic pairs: eight dizygotic twins and six sibling pairs with only a small
age difference [mean age difference ± standard deviation 4 3.5 years ± 1.4
years] among the members of the group III).
All 14 probands (individuals through whom family pedigrees were ascer-
tained) had been successfully treated for HNSCC at our department. Patients
were selected on the basis of their having several first-degree relatives. When the
patients were referred to our hospital for follow-up, they were asked permission
to contact their first-degree relatives to participate in this study. Patient and
tumor characteristics and the details of how many relatives of each patient
volunteered are summarized in Table 1. For staging of the HNSCC, the criteria
of the International Union Against Cancer (12) were used. In line with our earlier
studies (10,11), eight (57%) of 14 patients were determined not to be sensitive
to bleomycin-induced chromatid breaks (breaks per cell <1.0). Blood was drawn
from all of the participants after they signed an informed consent form. For all
twin pairs, the names and addresses were obtained from the National Nether-
lands Twin Registry (13). Zygosity of the twins was assessed by genotype
analysis of six unlinked microsatellite loci (with heterozygosities >90%) in two
different multiplex polymerase chain reactions (14). Zygosity analysis was per-
formed at the TNO Prevention and Health, Gaubius Laboratory, Division of
Vascular and Connective Tissue Research, Leiden, The Netherlands. The geo-
graphic distribution of both the twins and the family members of patients was
throughout the whole of The Netherlands. All subjects had given written in-
formed consent and the study design was approved by the local ethical commit-
tee.
It is important for the interpretation of the current study that smoking status of
the subjects was not included in the analysis. We and others (8,10,11) have
described earlier that exposure to tobacco smoke and alcohol (pack/unit years as
well as current smoking/drinking) does not influence the breaks per cell value
itself. This lack of effect is probably due to the 10 times dilution of the blood in
the medium and the culture period of 3 days for the chromosomal breakage assay
that diminishes any effects of tobacco or alcohol. Since, in the current study, we
were interested in the heritability estimate of the breaks per cell value and not in
the heritability of cancer, smoking or alcohol use was not included in the analy-
sis.
Chromatid Breakage Assay
Duplicate cultures were set up for each subject. Whole blood (0.5 mL) was
diluted 10 times in RPMI-1640 medium (BioWhittaker, Inc., Walkersville, MD)
with 2 mM L-glutamine (Life Technologies, Paisley, U.K.) supplemented with
15% fetal calf serum (Hyclone Laboratories, Inc., Logan, UT), 1.5% phytohe-
magglutinin (Life Technologies), 100 U/mL penicillin, and 100 mg/mL strepto-
mycin (BioWhittaker, Inc.). After the cells were cultured for 3 days at 37 °C and
5% CO2, they were incubated for 5 hours with bleomycin (30 mU/mL) (Lund-
beck, Amsterdam, The Netherlands). To arrest the cells at metaphase, 0.04
mg/mL Colcemid (Sigma Chemical Co., St. Louis, MO) was added to the cul-
tures 1 hour before harvesting. This yields cells in metaphase that were damaged
by the bleomycin in the late S–G2 phase of the cell cycle. The cells were swollen
in hypotonic solution (0.06 M KCl) and fixed in Carnoy’s fixative (3 : 1 [vol/vol]
methanol : acetic acid). After the cells were dropped on wet slides, the metaphase
spreads were air-dried and stained with Giemsa (Merck, Darmstadt, Germany).
Before 50 metaphase spreads were scored on each slide for the presence of
chromatid breaks, the slides (two slides per person) were coded to ensure ob-
jective “blinded” screening. The mean number of breaks per cell of 100 meta-
phases was used as a measure for the individual susceptibility. As has been
published previously (15), the scoring of gaps did not influence the outcome of
the assay and was omitted in further investigations. Since DNA damage was
introduced in late S–G2 phase of the cell cycle, chromosome aberrations such as
translocations were not present in the metaphases. Background levels (sponta-
neous) of chromatid breaks without damage induction by bleomycin that have
been determined in previous studies were very low (breaks per cell values of
approximately 0.06) and did not differ between patients and control subjects.
Therefore, data representing spontaneous breaks were not included.
Descriptive Statistics
Differences between groups with respect to mutagen sensitivity were assessed
by use of Student’s t test. The influences of age and sex on mutagen sensitivity
were determined by use of regression and likelihood methods. Intraclass corre-
lations were calculated by use of analysis of variance.
Heritability Estimation
A pedigree-based maximum likelihood method developed by Lange et al. (16)
was used to analyze resemblances among family members for chromatid breaks
Table 1. Characteristics of patients successfully treated for head and neck squamous cell carcinoma and whose first-degree relatives
participated in the study
Patient
No.
Tumor*
Chromatid breaks
per cell‡
No. of relatives§
Site Stage† Treatment Year of treatment Siblings Offspring
1 Larynx T1aN0 Radiotherapy 1992 1.27 0 6
2 Pharynx T1N0 Surgery 1993 1.18 2 4
3 Larynx T1N0 Surgery + radiotherapy 1982 1.28 7 0
4 Oral cavity T1N0 Surgery + radiotherapy 1993 1.13 0 4
5 Larynx T1N0 Surgery 1993 0.82 1 2
6 Larynx T2aN0 Radiotherapy 1992 0.72 0 2
7 Pharynx T4N1 Surgery 1992 0.79 1 1
8 Oral cavity T2N0 Surgery 1986 0.70 0 1
9 Oral cavity T1N0 Surgery 1992 0.38 2 2
10 Larynx T2N1 Surgery 1992 0.53 0 4
11 Oral cavity T1N0 Surgery 1992 1.02 5 2
12 Pharynx T2N2b Surgery + radiotherapy 1992 1.23 6 0
13 Pharynx T2N0 Surgery 1995 0.97 1 2
14 Larynx T1aN0 Surgery 1992 0.67 0 2
*Of some patients who have had more than one tumor, only the last tumor is mentioned in this table.
†The International Union Against Cancer criteria were used for staging (12).
‡These breaks per cell values have not been included for intraclass correlations but were used only for ascertainment correction by conditioning on probands in
the heritability estimation.
§Number of relatives that participated in the study (siblings and offspring).
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(used as a continuous phenotype). Data from twins and other family members
were analyzed simultaneously as so that the pedigree data consisted of a total of
53 pedigrees (twins and dizygote pairs were also put into the file as pedigrees
without a proband), a sample size of 135 subjects (including 50 monozygotic
twins), and 14 probands (whose data were evaluated separately and used only for
ascertainment correction by conditioning on probands). This ascertainment cor-
rection was needed because the pedigrees of the cancer patients were not a
random selection of the general population (16). Different models of familial
resemblance were fitted to the data. These models specified the variation in
phenotype to be due to the genotype and/or the environment. Sources of varia-
tion considered were additive: genetic influences (i.e., the sum of the effects of
the individual alleles across all loci that contribute to variation), common envi-
ronmental influences shared by family members who are living or have lived in
the same household, and a random environmental deviation that is not shared by
family members. These sources of variation can be considered as unobserved, or
latent factors, which affect the (continuous) phenotype, and can be estimated
from the observed patterns of resemblance between relatives. For each pedigree
of n individuals, a vector of observations (x) is defined, and a vector of expected
values (E[x]) can be calculated. E(x) can depend on fixed variables, such as sex
or age. The covariances among family members for that part of the dependent
variable that is not accounted for by the fixed variables depend on the relation-
ships between the pedigree members and on the genetic model assumed for
dependent variables. We have modeled the variance not accounted for by the
fixed effects as due to additive genetic influences, shared family environment,
and random environmental factors. For a given E(x) and expected covariances
matrix å , the ln-likelihood of obtaining the observation vector x is:
L = - 1/2 ln?(? - 1/2 @x - E~x!#8 (- 1 @x - E~x!# + constant,
where | | denotes the determinant of the matrix and 8 denotes transpose.
The joint likelihood of obtaining all pedigrees is the sum of the likelihood of
the separate pedigrees. Estimation involves selection of parameter values under
a specific model that maximizes the joint likelihood of all pedigrees. The
FISHER package of pedigree analysis (16) was used for genetic modeling. The
likelihoods obtained for the different models were compared with chi-squared
difference tests where x2 4 2(L1 − L0). L1 and L0 denote the ln-likelihoods of
the general (H1) hypothesis and a constrained (H0) hypothesis. The degrees of
freedom (df) for this test are equal to the number of constrained parameters
between H1 and H0 (17). The following parameters were estimated in the general
model: a sex effect and an age regression on means and three variance compo-
nents (genetic, shared, and unique environmental variances). First, it was tested
if additive genetic influences and common environmental influences could be
constrained at zero (hypothesis of no familial resemblance in chromatid breaks)
and next if either additive genetic influences or common environmental influ-
ences could be set to zero. The fixed effects on the means included a sex effect
and an age regression. The variance components part of the analysis applies to
the covariances of family members (while simultaneously modeling the age and
sex effect).
The conditional likelihood approach as implemented in the FISHER package
of pedigree analysis was used to correct for ascertainment. The heritability
estimate was calculated as the contribution of the genetic variance in the total
variance (genetic and environmental).
RESULTS
Descriptive Statistics
Plot of the data of the mean number of bleomycin-induced
chromatid breaks per cell of all of the 135 healthy study subjects
without cancer indicated a good approximation of the normal
distribution (Fig. 1). The effect of sex on the mean number of
breaks per cell was not statistically significant (x2 4 0.70 with
1 df; P 4 .40). The regression of age was positive (slope: b 4
0.007) and reached significance (x2 4 4.84 with 1 df; P 4
.027).
The mean breaks per cell level of HNSCC patients (probands)
was higher than that of their first-degree relatives without cancer
as well as the control group consisting of twins and sibling pairs
(Table 2). This difference was not statistically significant prob-
ably because of the small number of probands (n 4 14). In
earlier studies, we (18) and others (19) have scored patients
before and (at least 3 months) after treatment, and no influence
on the breaks per cell value was found. The higher rates of
breaks per cell in the probands are therefore not considered to be
due to the effects secondary to treatment. The relatively higher
breaks per cell value for siblings of the probands (group I)
compared with that for offspring of the probands (group II) may
be explained by the higher age of the former group.
One aspect of heritability is that the correlation in the out-
come of the assay between monozygotes is expected to be higher
than that in the dizygotes. To visualize the high agreement
within monozygotic twins for the mean number of breaks per
cell, a plot of the individual data (Fig. 2) is given. This shows
that the genetic influence for the susceptibility to bleomycin-
induced chromatid breaks may be large. For a 100% genetic
trait, the correlation between monozygotes is 1.0; for dizygotes,
on average it is 0.5. Table 3 summarizes the intraclass correla-
tions that were found for each group. The age-corrected intra-
class correlation in the dizygotes (correlation coefficient 4 .46)
in this study was statistically significantly less (P<.005) com-
pared with that seen in the monozygotes (correlation coefficient
4 .77). The cancer patients were not included in this variance
analysis. When the dizygotes were stratified by the presence of
a proband in the family, it appeared that the variance in the
siblings of the cancer patients was relatively large compared
with the dizygotes who were not related to cancer patients. For
both the age-corrected and noncorrected intraclass correlations,
however, the differences between groups of dizygotes were not
statistically significant. The very low correlation in the age-
corrected analysis implies a large influence of age in this par-
ticular group. The age difference within dizygotic pairs was
small (mean age difference ± standard deviation 4 3.5 years ±
1.4 years), while the siblings of cancer patients varied up to 16
years within a family, possibly explaining the relatively large
influence of age correction in the latter group. Another factor
related to the increased variation in the families of HNSCC
patients (groups I and II) compared with dizygotes not related to
cancer patients (group III) can be that some relatives of cancer
patients are likely to have an aberrant break per cell value due to
their inherited susceptibility to bleomycin-induced chromatid
breaks.
Fig. 1. Histogram of the frequency distribution of the mean number of chromatid
breaks per cell in the 135 subjects without a history of cancer. Data on the 14
probands (patients with head and neck cancer who were previously treated but
were tumor free for at least 1 year at the time of enrollment) are not included.
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Heritability Estimation
The actual heritability estimate was determined by use of a
pedigree-based maximum likelihood method in which the (con-
tinuous) breaks per cell data from twins and other family mem-
bers were analyzed simultaneously. The model that was fitted to
the data in the FISHER package of pedigree analysis specified
sex differences and age regression on the mean phenotype and
considered genetic, unique, and shared environmental influences
on variances and covariances between family members. The
largest likelihood should be for the full model. As shown in
Table 4, there was no evidence for the influence of a shared
family environment (x2 4 1.08 with 1 df; P 4 .29). The re-
duced model with the fixed shared environment does not fit the
data significantly worse than the full model. Our interpretation is
that shared environment does not contribute to familial resem-
blances. Genetic influences were statistically significantly
shown in the reduced model with fixed genetic variances that fits
the data significantly worse (x2 4 4.26 with 1 df; P 4 .036).
Particularly for the reduced model that excludes any familial
resemblance (genetic and shared environment), the likelihood is
statistically significantly reduced (x2 4 25.46 with 1 df;
P<.001). The heritability estimate of 75% was calculated (from
the most optimal reduced model that excludes the influence of a
shared environment) as the genetic variance (0.04775) divided
by the total variance (0.04775 + 0.01613 4 0.06388).
DISCUSSION
Heritability of persistent chromosomal damage is well estab-
lished for the severe chromosomal instability syndromes, such as
ataxia telangiectasia (AT) (20) and Fanconi anemia (21). How-
ever, it is a novel finding that the “hidden” chromosomal insta-
bility (since the breaks have to be induced by bleomycin to
observe the phenotype) that we describe in this study has a clear
genetic basis. Clustering of a high breaks per cell level in cancer-
prone families (22,23) already pointed toward a high heritability
estimate. Moreover, another type of cytogenetic analysis based
on the expression of aphidicolin-inducible common fragile sites
yielded a heritability estimate of 88% (24).
It is tempting to speculate that persons with a high suscepti-
bility phenotype in our study may, in fact, be heterozygotes of
the chromosomal instability syndromes. However, this hypoth-
esis is not supported by what is known about obligate heterozy-
gotes (e.g., parents of AT homozygotic patients). AT heterozy-
gotes, for instance, are estimated to represent 0.5%–2.8% of the
general population (25), while about 16% of the control persons
are hypersensitive to bleomycin-induced chromatid breaks (de-
fined as breaks per cell ø1.0) (15). Moreover, although obligate
AT heterozygotes do have a higher susceptibility to radiation-
induced chromatid breaks compared with control persons, they
have increased risk mainly for breast cancer (25) and not for
HNSCC. This may indicate that the levels of bleomycin-induced
chromatid breaks that we report are related to other genes pre-
disposing to HNSCC, although it cannot be excluded that genes
of other chromosomal instability syndromes are involved.
The relationship between a high susceptibility for chromatid
breaks and the development of environmentally related cancer
has been established in retrospective (8,10,11) and a limited
number of prospective (26,27) studies. The major conclusion
from these former studies is that the intrinsic susceptibility and
exposure to carcinogens act in concert to modulate cancer risk.
The great refinement of cancer risk assessment by use of the
susceptibility to bleomycin-induced chromatid breaks indicates
the importance of this biomarker. The fact that this factor has a
high heritability estimate underscores the relevance of genetic
factors for cancer development. This will probably be important
not only for HNSCC but also for all cancers in tissues that are in
direct contact with the environment, such as the colon and the
lung. The fact that a similar genetic factor does play a role in the
development of various types of cancers may explain cancer
proneness in families in which several types of cancers occur. It
has previously been noted that familial clustering of environ-
mentally related cancers does exist (28,29). It will be very in-
Table 2. Bleomycin sensitivity of different subjects related or unrelated to patients with head and neck squamous cell carcinoma
Subjects No. Mean breaks/cell (95% CI)* Mean age, y (95% CI)*
Probands† 14 0.91 (0.34 to 1.48) 66.9 (54.2 to 79.6)
Family members of probands 57 0.60 (0.14 to 1.05) 46.4 (19.6 to 73.3)
Group I: siblings of probands 25 0.72 (0.33 to 1.11) 59.7 (46.0 to 73.4)
Group II: offspring of probands 32 0.51 (0.12 to 0.90) 36.0 (22.3 to 49.7)
Volunteers not related to probands 78 0.59 (0.02 to 1.16) 36.4 (15.4 to 57.4)
Group III: dizygotes (14 pairs) 28 0.66 (−0.03 to 1.35) 37.6 (12.5 to 62.7)
Group IV: monozygotes (25 pairs) 50 0.55 (0.04 to 1.06) 35.6 (17.0 to 54.2)
*CI 4 confidence interval.
†All probands were patients with head and neck squamous cell carcinoma who were treated previously but who were tumor free for at least 1 year before
enrollment in this study.
Fig. 2. Scatterplot (the line represents the linear regression) of the individual
mean breaks per cell values of 25 pairs of monozygotic twins (person 1 and
person 2).
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teresting to screen the DNA of these families to link a high
susceptibility phenotype to mutations (or polymorphisms) in the
known susceptibility genes, such as p53 (also known as TP53),
BRCA1, and BRCA2 (30). The high heritability estimate that we
describe in this study for susceptibility to bleomycin-induced
chromatid breaks may also facilitate the discovery of new-
cancer predisposing genes. The phenotype, mean chromatid
breaks per cell, can be a valuable determinant because it may be
indicative of the cancer-prone phenotype and can be used as an
end point in these studies. It has the advantage that it can be
assessed before the cancer has occurred. This is very important
because the study of cancer-prone families is hampered by the
fact that the affected individuals often have already died.
When a common genetic defect is traced that is prevalent
among a relatively large part of the population (e.g., breaks per
cell level ø1.0), it may account for cancer predisposition in a
large proportion of the cancer cases in general compared with
the fraction that is due to inherited cancer syndromes (probably
<5%) (31). It is, therefore, important to recognize that the sus-
ceptibility to DNA damage varies in different individuals.
Avoidance of exposure to (environmental and occupational) car-
cinogens, especially in sensitive persons, may then become an
important factor in the prevention of cancer (32). The heritability
estimate of 75% challenges us to focus further research into
finding the gene(s) involved in the susceptibility to bleomycin-
induced chromatid breaks.
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Table 3. Summary of the familial correlations for bleomycin sensitivity measured as chromatid breaks per cell
Subjects
No. Intraclass correlation (95% CI)†
Families Subjects* Overall Corrected for age‡
Dizygotes
Participants enrolled as relatives of probands
Group I: siblings of probands 5 22 .42 (.00 to .71) .30 (−.14 to .64)
Group II: offspring of probands 10 30 .41 (.06 to .67) .40 (.05 to .66)
Participants not related to probands
Group III: dizygotic twins and siblings 14 28 .66 (.38 to .83) .64 (.35 to .82)
Monozygotes
Participants not related to probands
Group IV: monozygotic twins 25 50 .79 (.65 to .88) .77 (.63 to .86)
*All subjects are volunteers without a cancer history; to eliminate the selection bias, the probands (patients with head and neck squamous cell carcinoma) are not
included in the correlation analysis. Five persons could not be used in the correlation analysis because they were the only member within one family group.
†CI 4 confidence interval.
‡Overall intraclass correlation coefficient (.46) of dizygotes (groups I, II, and III combined) is statistically significantly (P 4 .0039) different from the correlation
coefficient (.77) observed for the monozygotes (group IV); no significant differences are present between groups I, II, and III with or without age correction.
Table 4. Contribution of the genetic and/or the environmental variance
component to the total variance in chromatid breaks per cell scores by use of
the FISHER package of pedigree analysis
Full
model*
No shared
environment
No genetic
influence
No familial
resemblance
ln-likelihood 136.528 135.989 134.409 123.805
x2 1.08 4.26 25.46
Degree(s) of freedom 1 1 2
P value (two-sided) .29 .036† <.001
Variances
Genetic 0.037 0.048‡ Fixed Fixed
Unique environmental 0.017 0.016 0.032 0.059
Shared environmental 0.011 Fixed 0.029 Fixed
Age regression 0.006 0.007 0.004 0.007
*The full model includes variances due to genetic, unique, and shared envi-
ronmental influences. Analysis of variance, by use of models that fitted to the
data in the FISHER package of pedigree analysis specifying sex differences and
age on the mean phenotype (breaks per cell value) and considered the contri-
bution of shared environment (environmental influences that persons have in
common when they are brought up in the same family), genetic influence, and
unique environment (environmental influences not related to familial resem-
blance) to the full model. Variance numbers are rounded to numbers with three
digits after the decimal.
†Genetic influences were significant, since the reduced model that fixes the
genetic variance fits the data statistically significantly worse.
‡Genetic influences explained 75% of the variances (heritability estimate 4
genetic variance [0.048]/total variance [0.064].
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